MA-INVICRO
4.3.2019 12:02:08 CET | Business Wire | Press release
Invicro LLC, a Konica Minolta company and icometrix jointly announced a partnership that will seamlessly offer the world’s most comprehensive breadth of imaging core lab services combined with the most robust FDA-cleared MRI informatics capabilities through automated workflows. Pharmaceutical sponsors will experience one point of contact for study site set-up and training which will harmonize with a single platform for data management, sharing and analytics.
Invicro is a leading provider of quantitative imaging biomarkers, core lab services and software solutions for research and drug development, and Belgium based icometrix is the world leader in software solutions to obtain clinically meaningful data from brain MRI and CT scans. This unique partnership combines streamlined core lab processes and advanced imaging technologies with FDA-cleared software for clinical trials. This collaboration will deliver a more efficient, flexible solution to help expedite drug discovery and development and provide better insights in disease diagnostics.
“We are excited to partner with icometrix to jointly offer global imaging core lab services and advanced analytics capabilities, resulting in workflows with highly-reliable and consistent data outcomes,” said Dr. Jacob Hesterman, Founding Partner and Head of R&D at Invicro. “Our Pharma and Biotech sponsors will benefit from the combination of established core lab operational excellence and analytics with robust, cutting-edge analysis tools in disease areas like Multiple Sclerosis, Alzheimer’s disease and Traumatic Brain Injury, enabling statistically powerful quantitation and fast, accurate decision-making.”
“We started icometrix to help patients with neurological disorders by providing more objective and consistent reading of brain scans in the clinical setting,” said Dr. Annemie Ribbens, VP Clinical Trials of icometrix . “As there is a huge interest to use our FDA cleared imaging measures in clinical trials and real-world studies, we are excited to partner with a global leader in this field.”
About
icometrix
icometrix
(Leuven, Belgium;
Chicago, IL, USA) is the world leader in software solutions to obtain
clinically meaningful data from brain MRI and CT scans. The fully
automated icobrain
software is FDA cleared, and today, it is part
of routine clinical practice in hospitals in Europe, Japan, India,
Canada, Brazil and Australia. Furthermore, icometrix
works with
the largest health tech and pharmaceutical companies on the evaluation
of trials of drugs for neurological diseases.
About Invicro
Headquartered in Boston, MA, Invicro was
founded in 2008 with the mission of improving the role and function of
imaging in translational drug discovery and development across all
therapeutic areas. Today, Invicro’s multi-disciplinary team provides
solutions to pharmaceutical and biotech companies across all stages of
the drug development pipeline (Phase 0-IV), all imaging modalities and
all therapeutic areas, including neurology, oncology, cardiology, and
pulmonary. Invicro’s quantitative biomarker services, advanced analytics
and AI tools, and clinical operational services are backed by Invicro’s
industry-leading software informatics platforms, VivoQuant®
and iPACS®
.
As part of the Konica Minolta precision medicine organization and with their sister company Ambry Genetics, Invicro develops and leverages the latest approaches in quantitative biomarkers including imaging, quantitative pathology and genomics. For more information, visit www.invicro.com .
About Konica Minolta
Konica Minolta, Inc. (Konica Minolta)
is a global digital technology company with core strengths in imaging
and data analysis, optics, materials, and nano-fabrication. Through
innovation, Konica Minolta creates products and digital solutions for
the betterment of business and society—today and for generations to
come. Across its Business Technologies, Healthcare, and
Industrial-facing businesses, the company aspires to be an Integral
Value Provider that applies the full range of its expertise to offer
comprehensive solutions to the customer’s most pressing problems, works
with the partners to ensure the solutions are sustainable, anticipates
and addresses tomorrow’s issues, and tailors each solution to meet the
unique and specific needs of its valued customers. Leveraging these
capabilities, Konica Minolta contributes to productivity improvement and
workflow change for its customers and provides leading-edge service
solutions in the IoT era. Headquartered in Tokyo and with operations in
more than 50 countries, Konica Minolta has more than 43,000 employees
serving approximately two million customers in over 150 countries.
Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For
further information, visit: https://www.konicaminolta.com/
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190304005056/en/
Contact:
Amanda Harrell VP, Global Marketing media@invicro.com
Social Media:
https://www.facebook.com/invicro/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
